Form 8-K - Current report:
SEC Accession No. 0001493152-24-046707
Filing Date
2024-11-19
Accepted
2024-11-19 08:48:35
Documents
15
Period of Report
2024-11-19
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41475
2 ex99-1.htm EX-99.1 18101
3 ex99-1_001.jpg GRAPHIC 25065
  Complete submission text file 0001493152-24-046707.txt   278231

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE kapa-20241119.xsd EX-101.SCH 3027
5 XBRL LABEL FILE kapa-20241119_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE kapa-20241119_pre.xml EX-101.PRE 24173
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 241473464
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)